In glioma, patient sample studies were shown to overexpress Fzd7, and both in vitro and in vivo interrogation revealed miR-206 targets Fzd7 while also decreasing cell proliferation, migration, and invasion (Zhou et al., 2019). Here, FZD7 is linked to central nervous system cancer.